Michael Penn: What The IRA Means For Oncology Innovation
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Michael Penn: What The IRA Means For Oncology Innovation
-
ナレーター：
-
著者：
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with Michael Penn, US Head of Reimbursement and Public Policy at Sanofi, to discuss how pricing policy, the Inflation Reduction Act (IRA), small-molecule incentives, orphan drug provisions, and Most Favored Nation (MFN) proposals could shape oncology innovation, patient access, and U.S. biopharmaceutical competitiveness.
Key Topics:
- IRA and Oncology: Late-stage research shifts, follow-on studies, lead asset selection.
- Small-Molecule Incentives: Pill penalty concerns, portfolio reassessment, biologic comparisons.
- Orphan Drug Policy: Orphan Cures Act provisions, rare disease investment, post-market indication development.
- Patient Access Risks: Fewer treatment options, affordability questions, unmet needs in oncology.
- U.S. Competitiveness: MFN proposals, global R&D incentives, comparisons with China and Europe.
Our new preprint on the IRA’s impact on late-stage R&D is available on our website and examines declines in small-molecule oncology research and orphan oncology studies.
Opinions expressed are those of the speakers. Recorded at ASCO 2026 on 5/31/26. The Vital Health Podcast is a production of Vital Transformation LLC © 2026.
See omnystudio.com/listener for privacy information.